Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michael Francis Harte"'
Autor:
Michael Francis Harte, Cathy Malcontenti-Wilson, Mark Frazzetto, Rosa Fida, Irma Kruszelnicki, Neil Wilson, Rodney J. Dilley, Soo San Wan, Ian D Phillips, P. Bukczynska, Max Joffe, Susan A. Charman, Stephen Su, David M. Shackleford, Andrew F. Wilks, Yue Wang, Christopher J. Burns, Emmanuelle Fantino, Bing Wang
Publikováno v:
Molecular Cancer Therapeutics. 8:3036-3045
CYT997 is a wholly synthetic compound that possesses highly potent cytotoxic activity in vitro through inhibition of microtubule polymerization. CYT997 blocks the cell cycle at the G2-M boundary, and Western blot analysis indicates an increase in pho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b50aebffc818e5cc6d0bda0445eb1ad
https://doi.org/10.1158/1535-7163.mct-09-0076
https://doi.org/10.1158/1535-7163.mct-09-0076
Autor:
Christopher Christophi, Michael Francis Harte, Gregg Smith, Valentina Dubljevic, Andrew F. Wilks, Christopher J. Burns, Andrew K. Powell, Cathy Malcontenti-Wilson, Stuart Nelson, Max Joffe, Ian D Phillips, Steven D. Shnyder, David J. Segal, Patricia A. Cooper, Emmanuelle Fantino
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 339(3)
The orally active microtubule-disrupting agent (S)-1-ethyl-3-(2-methoxy-4-(5-methyl-4-((1-(pyridin-3-yl)butyl)amino)pyrimidin-2-yl)phenyl)urea (CYT997), reported previously by us (Bioorg Med Chem Lett 19:4639-4642, 2009; Mol Cancer Ther 8:3036-3045,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93ab00ba4823ed88a21db623c941f3cd
https://pubmed.ncbi.nlm.nih.gov/21917561
https://pubmed.ncbi.nlm.nih.gov/21917561
Autor:
Max Joffe, Susan A. Charman, Michael Francis Harte, Harrison Sikanyika, David M. Shackleford, Andrew F. Wilks, Stephen Su, C. Elisabet Tranberg, Emmanuelle Fantino, Xianyong Bu, Neil Wilson, Christopher J. Burns
Publikováno v:
Bioorganicmedicinal chemistry letters. 19(16)
CYT997 was discovered as a potent tubulin polymerization inhibitor possessing potent cytotoxic activity against a range of cancer cells. Details of SAR studies, pharmacokinetic investigations and synthesis of compounds leading to the discovery of CYT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9d0980f28c1e5ed7d17ed9812e165cb
https://pubmed.ncbi.nlm.nih.gov/19616947
https://pubmed.ncbi.nlm.nih.gov/19616947
Autor:
Marilena Giarrusso, Stephen Su, Michael Francis Harte, Emmanuelle Fantino, Herbert R. Treutlein, Margarita Kurek, Max Joffe, Christopher J. Burns, Xianyong Bu, Jun Zeng, Pasquale Razzino, Andrew F. Wilks, Soo San Wan, F. S. Legge
Publikováno v:
Bioorganicmedicinal chemistry letters. 19(4)
A series of 2-(alpha-methylbenzylamino) pyrazines have shown to be potent inhibitors of the FMS tyrosine receptor kinase. Details of SAR studies, modeling and synthesis of compounds within this series are reported.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::121c1c34cc3ef984ddb46b05dc75f2ac
https://pubmed.ncbi.nlm.nih.gov/19128971
https://pubmed.ncbi.nlm.nih.gov/19128971